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Abstract
Objective The objective of the study was to identify patients who may benefit from local treatment in recurrent colorectal
liver metastases.
Materials and methods A total of 51 consecutive patients were treated for hepatic recurrence(s) after an initial partial
hepatic resection. Surgery was considered as the primary treatment option for eligible patients. Patients with a small liver
remnant after major hepatectomy were treated with radiofrequency ablation (RFA) or stereotactic body radiation therapy
(SRx). SRx was given as an outpatient, emerging local treatment option for patients with intra-hepatic recurrences not
eligible for surgery or RFA. Partial liver resection was performed in 36 patients (70%), RFA in ten patients (20%), and SRx
in five patients (10%).
Results Median hospital stay was 7 (range, 3–62) days with a morbidity of 16% without in-hospital death. None of the
patients received adjuvant chemotherapy. There was no difference in recurrence or survival between the three treatment
modalities. Overall 5-year survival was 35% with an estimated median survival of 37 months. Patients with a disease-free
interval between first hepatectomy and hepatic recurrence less than 6 months did not survive 3 years.
Conclusions Resection, RFA, and SRx can be performed safely in patients with recurrent colorectal liver metastases and
offer a survival that seems comparable to primary liver resections of colorectal liver metastases.
Keywords Colorectal liver metastases . Recurrent hepatic
metastases . Hepatic resection . Radiofrequency ablation .
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Introduction
Colorectal cancer is one of the most common malignancies
and a leading cause of death. Liver metastases develop in
50–60% of patients,1,2 and surgical resection currently
represents the best treatment for long-term survival and
even cure in patients with colorectal liver metastases.
Despite the curative intent, more than 60% will suffer
from recurrence after liver resection, the liver being the
most common location.3 Since liver resection has become
safer through improvements in surgical techniques and
per-operative management, repeat hepatic resection is
being more frequently performed in patients with hepatic
recurrences. Several studies on repeat hepatic resection
have been reported in the last decade.4–9 Recent techno-
logic advances have also made local ablative treatments for
liver tumors accessible.10 Patients with small central
recurrences after a prior major liver resection and patients
who are poor candidates for surgery are often treated by
radiofrequency ablation (RFA). Stereotactic body radiation
therapy (SRx) is another emerging local treatment option
for patients with intrahepatic malignancies not eligible for
surgery or RFA.11
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Unfortunately, most patients who develop a recurrence
after colorectal liver surgery cannot undergo secondary
procedures. Systemic chemotherapy (CTx) is used in these
patients with increasing median survival rates with current
multimodality treatments.12,13 Approximately 5% to 10%
of patients who develop hepatic recurrence after liver
resection are amenable to a second resection or local
ablative treatment. Most reports are based on small
populations or on combined populations from several
centers. In this article, we report our experience in a single
center with local treatment for recurrent liver disease. The
purpose of this study was to evaluate prognostic factors for
overall, disease-free survival and to identify patients who
might benefit most from secondary local treatment.
Patients and Methods
Between March 1988 and October 2007, 520 partial liver
resections were performed in our center because of
colorectal liver metastases. Fifty-one patients were treated
for hepatic recurrences after a first partial hepatic resection
for colorectal liver metastases.
Criteria for repeat liver treatment were similar to those for
first hepatectomy: the presence of technically removable
metastases (preserving at least two segments of the liver
parenchyma), and the possibility of an oncological radical
procedure. Surgery was considered as the primary treatment
option for eligible patients. Nowadays, surgery provides the
best outcome for the treatment of colorectal liver metastases.
To date, no randomized trial has been performed between
resection versus local ablation. Therefore, in colorectal
metastases, surgery is still the gold standard.14,15 For
patients with a small liver remnant after major hepatectomy,
RFA or SRx were alternatives if the metastases were
<3 cm.10,11 RFA was first treatment option, but in case of
ill location of the metastases (nearby main vessel and/or
bile ducts), SRx was the alternative.
Patients with extrahepatic disease that was resectable
were also included in this study.
RFA was performed with a 200-W RF generator and the
cluster RF electrode was introduced into the hepatic
malignancies during laparotomy or by imaging guidance
percutaneously.10 SRx was mostly given in three fractions
of 15 Gy, and the prescription isodose was 65%.11
Data analyzed included demographics, pathological
tumor–node–metastases stage of the primary tumor,
maximum size and number of metastases on computed
tomography (CT), plasma carcinoembryonic antigen (CEA)
level, type of liver surgery, overall duration of hospital
stay, complications, radicality, site, and treatment of
recurrence.
Overall survival and disease-free survival (DFS) were
measured from the start of treatment of hepatic recur-
rence. The nomenclature and extent of hepatic resection
were recorded according to the terminology defined by
Couinaud.16 We defined a positive surgical margin as the
presence of exposed tumor along the line of transaction.
After partial hepatectomy, patients routinely underwent a
physical examination and determination of CEA level and
abdominal/chest CT or ultrasonography every 4 months for
the first year, every 6 months the second year, and once a
year thereafter. Endoscopic surveillance was performed
after 1 year and thereafter depending on the findings.
The nonparametric log-rank test was used to identify
prognostic variables associated with survival after the
second liver resection, with significance at p=0.05.
Results
First Partial Liver Resection
Clinical data of the first partial hepatectomy are depicted for
all 51 patients in Table 1. At the time of the first hepatectomy,
one patient had extrahepatic disease of the lung and
underwent a pulmonary lobectomy. In another patient a
peritoneal metastasis was detected during laparotomy and
resected simultaneously with the liver metastases. The
Table 1 Clinical Data on the First and Second Local Treatment
First hepatectomy
N=51
Second local
treatment N=51
Neoadjuvant CTx
Yes 26 11
No 25 40
No. of tumorsa 2 (1–8) 1 (1–5)
Size of tumor (cm)a 3 (1–10) 2.5 (1–7)
Preoperative CEA-level
(μg/L)a
17 (1–5315) 10 (1–126)
Tumor distribution
Unilobar 30 44
Bilobar 21 7
Liver surgery
Extended hemihepatectomy 2 –
Hemihepatectomy 16 6
Extra-anatomic 33 30
RFA – 10
SRx – 5
Morbidity (%) 12 (24%) 8 (16%)
Mortality (%) 0 0
Hospital stay (days) 8 7
Positive surgical margin (%) 7 (14%) 2 (4%)
aMedian
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resection margin at permanent section was microscopically
not free of tumor in seven patients. There was no in-hospital
death, 12 patients had per-operative complications without
surgical re-intervention, and median hospital stay was
8 (range 4–72) days.
Intrahepatic Recurrences
Clinical data of the 51 patients who underwent treatment
for recurrent metastases are depicted in Table 1. The
median interval between first hepatectomy and recurrent
hepatic metastases was 11 (range, 3–78) months. Partial
liver resection was performed in 36 patients (70%), RFA in
ten patients (20%, two open and eight percutaneous
procedures) and SRx in five patients (10%). One patient
showed peritoneal disease, and the omentum was resected.
One patient showed ingrowth of the diaphragm, and a
partial resection of the diaphragm was performed. Two
patients received additional SRx for solitary lung metasta-
ses and one patient for a solitary costal metastasis. There
was no in-hospital death. Eight patients had per-operative
complications without surgical intervention, and median
hospital stay for patients who underwent resection or open
RFA was 7 (range, 3–65) days. None of the patients were
treated with adjuvant CTx.
Follow-Up
Median follow-up from secondary treatment for recurrences
were 22 (3–115) months. Thirty-two patients (63%)
developed a secondary recurrence. Five patients underwent
palliative systemic CTx for pulmonary metastases. One
patient developed a local recurrence in the pelvis and
underwent resection. Of the 26 patients with intra-hepatic
recurrence, 14 patients were treated with palliative CTx or
analgesic treatment and 12 patients with repeat local
treatment. Disease-free survival after treatment of hepatic
recurrence was 47% at 1 year, and estimated median DFS
was 11 months.
Survival
Overall 3-year and 5-year survival rates were 55% and
35%, respectively, with an estimated median survival of
37 months. The results of univariate analysis of overall
3-year survival after treatment of recurrent hepatic metas-
tases are depicted in Table 2. Patients with an interval of
more than 6 months between first hepatectomy and second
local treatment and patients with metastases detected
synchronously with the primary tumor have a significantly
better survival (p=0.01 and p=0.006, respectively). After a
median follow-up of 22 months, 18 patients died, and 33
Table 2 Univariate Analysis of Prognostic Factors for Survival after
Repeat Treatment for Recurrence of Intrahepatic Disease
Prognostic factor N (%) Survival
3 years (%)
Significance
(p)
Age
≤60 25 54
>60 26 56 0.57
Gender
Male 34 (67) 64
Female 17 (33) 19 0.05
Site of primary tumor
Colon 31 (61) 56
Rectum 20 (39) 54 0.71
First metastases
Synchronous 32 68
Metachronous 19 26 0.006
pT primary tumor
T0-2 6 100
T3-4 45 50 0.09
pN primary tumor
Negative 26 50
Positive 25 59 0.50
Interval (months) of first hepatectomy to date of recurrence
≤6 6 0
>6 45 62 0.01
Second metastases
No. of tumors
1 30 54
>1 21 72 0.86
Size of tumor (cm)
≤5 47 58
>5 4 33 0.85
Neoadjuvant CTx
Yes 11 64
No 40 53 0.68
CEA
≤50 43 54
>50 4 100 0.66
Distribution of metastases
Unilobar 44 57
Bilobar 7 38 0.47
Extrahepatic disease
Absent 46 59
Present 5 0 0.32
Type of treatment
Resection 36 53
RFA/SRx 15 59 0.71
Positive lymph nodes
No 49 36
Yes 2 36 0.62
Margin of hepatectomy
R0 34 42
R1 2 0 0.72
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patients are alive of whom 24 patients are alive without
disease.
Discussion
Without treatment, patients with colorectal liver metastases
have a life expectancy of less than 1 year.17 With the
increasingly efficient chemotherapy regimens, median
survivals currently reach 16–22 months.12,18 In our study
group, median overall survival was 37 months after local
treatment of the intra-hepatic recurrences. Our study reports
overall 3-year and 5-year survival rates of 55% and 35%
after local treatment of recurrent colorectal liver metastases,
which is comparable to the outcome in our series of first
hepatectomies that we published previously.19 Low mor-
bidity (16%) and no in-hospital death showed that repeat
local treatment for colorectal hepatic metastases can be
performed safely. These results are comparable with those
of other studies (Table 3).4–9
Improvements in surgical techniques and per-operative
management increase the number of repeat hepatic resec-
tion in patients with isolated hepatic recurrence.20 A
reduction of blood loss, which is associated with preoper-
ative morbidity and mortality, was obtained over the past
decade with a corresponding decrease of transfusion
requirements. This was related to an increase in parenchy-
mal-sparing resection, performing of resections with a low
central venous pressure, and with the advent of portal
pedicle ligation maneuvers.21 The extent of liver resection
depends on the size, location, distribution, and the relation
of the major afferent and efferent vasculatures and bile
ducts to liver metastases. More wedge resections can be
performed because several recent studies have indicated
that a margin less than 1 cm is not a contraindication to
resection of colorectal liver metastases.22–25 Moreover, a
margin of 1 mm seems to be appropriate, despite the fact
that the pathological report will define the procedure as a
microscopic irradical resection.24 Current techniques with
ultrasonic dissectors aspirate a part of the liver parenchyma
interposed between the specimen and the normal liver,
making assessment of the true margin difficult.
The rate of wedge resection in our study was higher in
repeat hepatectomies than in the initial hepatectomies
because the extent of resection at repeat hepatectomy
depended on the amount of remnant liver after first
hepatectomy. It seems that the extent of hepatic resection
does not influence the outcome of secondly resected
patients, providing that all metastatic tissue is removed,
which is in agreement with the results of Zorzi et al.26
A deeper knowledge of the segmental anatomy of the
liver16 and the routine use of intraoperative ultraso-
nography has eliminated the need of “blind” extensive
resection, therefore limiting the amount of resected
parenchyma.
The present study shows that 3-year survival rate is
significantly better for those patients with an interval of
more than 6 months between first hepatectomy and hepatic
recurrence. Patients who had an interval shorter than
6 months did not survive longer than 3 years (median
estimated survival 27 months). This is in agreement with
the results of Bhattacharjya et al. who suggest that tumors
recurring early following liver resection are less likely to be
amenable to re-resection because of adverse tumor charac-
teristics and a higher potential for spread of disease.27 They
concluded in their study that aggressive follow-up during
the first 6 months was not advisable because none of the
patients could benefit from local treatment. Together with
our results, it may be concluded that patients with intra-
hepatic recurrences within 6 months after partial hepatec-
tomy should be offered systemic CTx because the median
survival of patients who were treated with modern systemic
chemotherapy also may exceed 20 months.28
The other significant factor was synchronicity of the
metastases of the primary tumor. Patients with synchronous
metastases showed a significantly (p=0.006) improved
survival after intra-hepatic recurrences that could be treated
by local treatment than patients with metachronous disease.
Table 3 Literature Review of Large Series (>50 pts) of Repeat Local Treatment in Patients with Recurrent Colorectal Liver Metastases in the Last
10 Years
Authors Year No. of centers No. of patients Mortality (%) Morbidity (%) Median survival
(months)
Survival
3 years 5 years
Adam4 1997 1 64 0 19 46 60 41
Sugarbaker7 1999 20 170 NR 19 34 45 32
Yamamoto9 1999 1 70 0 11 31 48 31
Petrowsky5 2002 2 126 1.6 28 37 51 31
Thelen8 2006 1 94 3.1 23 NR 55 38
Shaw6 2006 1 66 0 18 56 68 44
Present series 2008 1 51 0 16 37 55 35
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A clear explanation cannot be given besides the fact that the
number of patients is small.
Despite favorable results of repeat hepatic resection for
patients with recurrent colorectal liver metastases, there
remains controversy regarding the optimal treatment for
such patients. The advent of minimally invasive therapies
such as RFA or SRx may offer less procedure-associated
morbidity and mortality. A concern is the variable rate of
local recurrence that can follow such targeted therapies.
Lesions treated with RFA have local recurrence rates of 4%
to 55%.10,29Crude local control rates of 78–100% are
reported in tumor-based analysis after SRx.30 RFA has
achieved an important role for patients unfit for surgery
with small (<3 cm) liver metastases. Some authors even
stated that the time has come to perform a randomized trial
between resection and other local ablative methods.31 In
our center, resection is still the gold standard.15 The
treatment failure rate after radiofrequency ablation even in
small tumors is higher than local recurrence rates after
definitive resection. Again, the results of the local ablative
treatments are promising, and therefore, local ablation
therapies may be applied in patients not suitable for surgery
because of ill location of the tumor and/or the physical state
of the patients.
In the current study, no difference was found in
recurrence or survival in patients treated with resection,
RFA, or SRx. In our practice, patients with small central
located intra-hepatic recurrences after a prior major liver
resection are often treated by RFA. RFA could be
performed percutaneously, avoiding the complications
associated with partial hepatectomy. RFA and SRx may
be used in conjunction with operative resection to increase
resectability. Furthermore, these alternatives to surgery may
increase the population considered for treatment of hepatic
recurrences in case of patients unfit for operation. A
possible algorithm for different treatment modalities of
recurrent liver metastases is proposed in Fig. 1.
Conclusion
These repeat local treatments can be performed safely,
without greater risk than first liver resections, and offer a
survival rate as good as first liver resections. Resection
should be the preferred approach, but RFA and SRx are
good alternatives with a beneficial outcome. Patients with
intra-hepatic recurrences within 6 months after first partial
hepatectomy should be offered systemic chemotherapy.
Recurrent liver metastases
Disease-free interval < 6 months Disease-free interval > 6 months
Small liver remnant*
Metastases nearby
biliary ducts/vessels Resection
*  <2 segments
Yes
NoYes
RFASRx
No
CTx
Figure 1 Algorithm.
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